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ABSTRACT
Introduction: Endocrine therapy has played an important role in the management 
of ER positive breast cancer over recent decades. Despite this, not all patients respond 
equally to endocrine intervention, which can lead to resistance, associated disease 
relapse and progression. Previous reports suggest that endocrine agents themselves 
may induce an invasive phenotype in ER positive breast cancers with low/aberrant 
expression of E-cadherin. Here we investigate this phenomenon further and provide 
data supporting a role for the ER co-receptor, PELP-1, in mediating an adverse 
response to endocrine agents.
Materials and Methods: The effects of tamoxifen, fulvestrant and estrogen 
withdrawal (as a model for aromatase inhibitor therapy) on the invasive and migratory 
capacity of endocrine-sensitive MCF-7 and T47D cells, in the presence or absence 
of functional E-cadherin and/or PELP-1 (using siRNA knockdown), was assessed 
via Matrigel invasion and Boyden chamber migration assays. The effects of these 
endocrine therapies alongside E-cadherin/PELP-1 modulation on cell proliferation 
were further assessed by MTT assay. Western blotting using phospho-specific 
antibodies was performed to investigate signalling pathway changes associated with 
endocrine-induced changes in invasion and migration.
Results: Both tamoxifen and fulvestrant induced a pro-invasive and pro-migratory 
phenotype in ER positive breast cancer cells displaying a high basal expression of 
PELP-1, which was augmented in the context of poor cell-cell contact. This process 
occurred in a Src-dependent manner with Src inhibition reversing endocrine induced 
invasion/migration. While this adverse response was observed using both tamoxifen 
and fulvestrant therapy, it was not observed under conditions of estrogen withdrawal.
Conclusions: Our data confirms previous reports that anti-estrogens induce an 
adverse cell phenotype in ER+ breast cancer, particularly in the absence of homotypic 
cell contact. These results implicate E-cadherin and PELP-1 as potential biomarkers 
when deciding upon optimum adjuvant endocrine therapy, whereby tumours with high 
PELP-1/low E-cadherin expression may benefit from estrogen withdrawal therapy via 
aromatase inhibition, as opposed to ER modulation/antagonism.
INTRODUCTION
Over the past decades, the treatment options for 
ER+ breast cancer have improved dramatically, with 
patients now likely to receive the ER modulator tamoxifen 
as a first line agent in the pre-menopausal setting [1], or 
fulvestrant as a second-line agent in locally advanced 
and metastatic breast cancer [2]. More recently the use 
of third generation aromatase inhibitors has largely 
replaced the use of other agents in both the adjuvant and 
metastatic setting, particularly in the post-menopausal 
age group [1]. Despite the proven efficacy of these 
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agents, not all patients respond equally, which can lead 
to the acquisition of endocrine resistance and associated 
disease relapse or progression. Whilst adjuvant tamoxifen 
significantly reduces both cancer recurrence and cancer 
related mortality, recurrence amongst ER+ patients whilst 
still on tamoxifen therapy lies in the region of 25% at 10 
years, with around 60% of these recurrences occurring 
within the first 5 years [3]. In a similar manner, patients 
with metastatic ER+ disease treated with fulvestrant 
monotherapy demonstrate an objective response to 
treatment in only around a third of cases, with a median 
time to progression of around 8 months [4], although 
combination treatments can be more successful [5, 6]. To 
date, biomarkers predictive of endocrine response outside 
of the ER remain scarce and better elucidation of key 
molecular mechanisms that predict poor response to such 
treatments can aid in stratification of patients for more 
appropriate treatments.
Src is a 60kDa non-receptor protein tyrosine kinase 
that has been implicated in several important oncogenic 
pathways [7]. As such, Src is implicated in several critical 
cellular processes in breast cancer, including proliferation, 
angiogenesis, motility and invasion [8, 9] and plays an 
important role in signalling cross-talk, including those 
mediated by the ER [10]. Src activity is increased in 
invasive compared with non-invasive breast cancer cell 
lines and invasion may be suppressed by treatment with 
a pharmacological Src inhibitor in these circumstances 
[11]. Meanwhile, activated Src expression may attenuate 
the response to tamoxifen and is associated with poorer 
survival in ER+ breast cancer patients [12]. Metastatic 
breast cancer patients with elevated Src expression are 
also associated with poorer disease specific survival [13]. 
Src may itself be activated by estrogen through interaction 
with the ER via its Src homology 2 domain (SH2), 
allowing further downstream signalling of MAPK and 
AKT, among others, through its receptor tyrosine kinase 
action [7]. Factors which help regulate this cascade remain 
unclear but may include the ER co-factor PELP-1. 
PELP-1 is a large multi-domain protein which plays 
an important role in the modulation of several signalling 
cascades, including mediating the non-genomic actions 
of the ER [14]. Clinically, PELP-1 has been found to be 
an independent prognostic predictor of breast cancer-
specific and disease-free survival [15] and has also 
been shown to be a marker associated with tamoxifen 
resistance, with patients whose tumours had high levels 
of cytoplasmic PELP1 responding poorly to treatment 
[16]. The protein has several known functions, such as 
interaction with nuclear receptors via its nuclear receptor 
(NR)-interacting boxes (LXXLL motifs) [17] and histone 
activation, through a histone binding regions located at the 
C-terminus [18, 19], among others. Importantly, PELP-1 
contains a several PXXP motifs which facilitate interaction 
with proteins containing Src homology 3 (SH3) domains 
[14] permitting PELP-1-mediated activation of Src family 
kinases. Through this interaction PELP-1 can interact with 
several proteins that control the cell cytoskeleton, cell 
migration and metastases [20]. 
Previously we reported that a loss of the cell 
adhesion molecule, E-cadherin, in ER+, endocrine-
sensitive breast cancer cell models resulted in an adverse, 
invasive response to the endocrine agents tamoxifen 
and fulvestrant [21]. Given the potential importance of 
these observations here we have explored further the 
cellular mechanisms that promote an adverse response 
to endocrine agents, and suggest a role for PELP-1 as a 
central mediator of this phenotype.
RESULTS
Tamoxifen and fulvestrant, but not E2-
withdrawal, promotes invasion and migration of 
ER+ breast cancer cells  
We first examined the ability of the endocrine agents 
tamoxifen, fulvestrant and E2-withdrawal (as a model 
of aromatase inhibition) to promote the invasion and 
migration of ER-positive breast cancer cells as previously 
reported [21]. MCF-7 cells are poorly invasive in vitro 
[22] and their invasive capacity was not significantly 
affected by estrogen withdrawal (Figure 1A). In contrast 
both tamoxifen (Figure 1B) and fulvestrant treatment 
(Figure 1C) resulted in a significant increase in cell 
invasion compared to control (untreated) cells.
In a similar manner, the capacity of MCF7 cells to 
migrate across a fibronectin-coated, porous membrane was 
determined and compared to control conditions. In this 
case both tamoxifen (Figure 1E) and fulvestrant therapy 
(Figure 1F) resulted in a significant increase in the number 
of migratory cells whilst, in contrast, estrogen withdrawal 
resulted in reduced migration (Figure 1D).
E-cadherin loss augments the pro-invasive and 
pro-migratory effects of endocrine agents in ER+ 
breast cancer cells 
Previously the absence of intercellular adherens 
junction contacts has been suggested to enhance the 
pro-invasive and pro-migratory effects of tamoxifen and 
fulvestrant [21]. We therefore wished to investigate this 
phenomenon further. An siRNA approach was taken 
to suppress expression of the E-cadherin gene (CDH1) 
which resulted in a loss of E-cadherin protein, an effect 
that was maintained up to 6 days following exposure 
of cells to the agent (Figure 2A). siRNA-mediated 
suppression of E-cadherin resulted in a significant increase 
in  cell invasion (Figure 2B) and migration (Figure 2C); 
interestingly, the ability of tamoxifen (Figure 2B and 
2C) and fulvestrant (Figure 2D and 2E) to promote cell 
invasion and migration was significantly augmented in 
the absence of E-cadherin expression whereas estrogen 
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withdrawal still did not promote an adverse cellular 
response (Figure 2F and 2G). 
To determine whether E-cadherin knockdown 
altered the anti-proliferative response to endocrine agents, 
siRNA-treated MCF7 cells were subject to an MTT assay 
in the presence and absence of tamoxifen, fulvestrant 
and estrogen withdrawal. These data (Figure 2H–2J) 
confirmed MCF-7 cells were responsive to anti-hormone 
and estrogen withdrawal, irrespective of E-cadherin 
expression status and suggests that the observed changes 
in invasion and migration were irrespective of cellular 
proliferative capacity.
Tamoxifen and fulvestrant-induced invasion and 
migration involves Src kinase activation
Tamoxifen can activate Src kinase [23] and Src 
is known to be a key regulator of cellular invasion and 
migration in acquired tamoxifen-resistant MCF-7 cells 
[24]. We therefore next explored whether Src kinase 
might play a role in the invasive behaviour observed after 
endocrine treatment of MCF-7 cells. In cells treated with 
either tamoxifen of fulvestrant, levels of phosphorylated 
Src (Y418) were seen to increase, an effect that occurred 
irrespective of E-cadherin status (Figure 3A). In contrast, 
estrogen withdrawal led to the suppression of Src activity 
in these cells. 
We next sought to determine the functional relevance 
of Src activity in our model by performing invasion 
and migration assays on endocrine-treated, E-cadherin 
suppressed cells in the presence of the pharmacological 
Src inhibitor Saracatanib (1 µm). Treatment of cells with 
Sarcanitib resulted in the inhibition of Src kinase activity 
(Figure 3B) and a significant reduction in the observed 
invasion (Figure 3C) and migration (Figure 3D) of MCF-7 
cells treated with tamoxifen ± CDH1 siRNA.
Sarcanitib was found to suppress cell proliferation in 
both wild type and E-cadherin - deficient cells (Figure 3E) 
although the combined effect of Sarcanitib and tamoxifen 
therapy had no additional effect on cell proliferation 
compared to tamoxifen alone. 
Tamoxifen and fulvestrant-induced invasion and 
migration, in MCF7 cells, involves an increase in 
ERK 1/2 and a decrease in AKT signalling
In addition to exploring Src activity and expression 
we further investigated whether ERK and AKT, known 
to be involved in Src-mediated pro-invasive signalling 
pathways, were altered in response to endocrine agents in 
the context of E-cadherin loss. 
In a similar fashion to Src kinase, phosphorylated 
ERK 1/2 levels were elevated in cells treated with either 
tamoxifen of fulvestrant, irrespective of E-cadherin 
status. Again, and in contrast to this, estrogen withdrawal 
led to the suppression of ERK 1/2 activity in these cells 
(Figure 4A). Phosphorylated AKT levels (Ser473) were 
reduced in cells treated with tamoxifen and fulvestrant, 
an effect that also appeared independent of E-cadherin 
status; estrogen withdrawal also suppressed AKT activity 
(Figure 4B). 
The functional relevance of ERK 1/2 and AKT 
activity was assessed by performing invasion and 
migration assays on endocrine-treated, E-cadherin 
Figure 1: Endocrine agents induce invasion and migration of ER+ breast cancer cells in vitro. MCF7 cells were treated with 
tamoxifen, fulvestrant (both at 100 nM) or conditions of estrogen withdrawal prior to seeding into Matrigel- or fibronectin-coated Boyden 
chambers to measure cellular invasion (A–C) and migration (D–F) respectively. 
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suppressed cells in the presence of the pharmacological 
inhibitors (U0126, 10 µm and Perifosine, 10 µm, 
respectively). 
Treatment with U0126 resulted in a significant 
reduction in ERK 1/2 expression (Figure 4C) and a 
significant reduction in observed invasion (Figure 4D) 
and migration (Figure 4E) of MCF-7 cells treated with 
tamoxifen and/or CDH1 siRNA. U0126 was also found to 
suppress cell proliferation, assessed by MTT assay, in both 
wild type and E-cadherin suppressed MCF7 cells (Figure 
4F). Meanwhile, while Perifosine resulted in a significant 
reduction of phosphorylated AKT expression (Figure 4G), 
and a reduction in cell proliferation (Figure 4H), AKT 
inhibition had no significant effect on either cell invasion 
(Figure 4I) or migration (Figure 4J) in these cells.
PELP-1 expression is augmented in MCF7 cells
PELP1 is known to interact with Src family kinase 
SH3 domains via its PXXP motifs [14] allowing PELP1 
to promote the activation of these enzymes. Given that 
PELP1 also binds to the ER, PELP1 may thus act to bridge 
Src with the ER as an alternative means of signalling, 
compared with direct activation of Src by the ER via the 
SH2 domain. Given that we have observed an invasive 
phenotype in response to ER modulatory agents, but not 
E2 withdrawal, and the fact that that this phenotype was 
associated with an increase in Src signalling, we wished to 
investigate whether PELP-1 played a role in this adverse 
response. 
Examining the levels of PELP-1 in MCF7 cells 
revealed that these cells had high levels of protein expression 
as compared to a panel of other ER+ breast cancer cell lines 
(Figure 5A). Using two ER+, endocrine sensitive cell models 
that differed intrinsically in PELP-1 expression (MCF7 and 
T47D), we repeated the invasion and migration assays in 
response to tamoxifen treatment +/– E-cadherin knockdown. 
In contrast to MCF7 cells (high PELP1), treatment with 
tamoxifen led to no significant change in invasion (Figure 
5B) or migration (Figure 5C) in T47D cells (low PELP1), 
both in the presence and absence of E-cadherin expression. 
Interestingly, tamoxifen and fulvestrant both augmented 
the expression of PELP1 in MCF7 cells (Figure 5D), while 
E2 withdrawal suppressed PELP1 expression. Meanwhile 
Figure 2: E-cadherin loss augments pro-invasive and pro-migratory actions of tamoxifen and fulvestrant. (A) MCF-7 
cells were treated with CDH-1 siRNA and harvested 1–6 days post treatment and cellular lysates subjected to Western blot analysis to 
investigate whether E-cadherin expression remained suppressed following siRNA treatment. The effects of tamoxifen (B, C, H), fulvestrant 
(D, E, I) or estrogen withdrawal (F, G, J) were determined on the invasive, migratory and proliferative capacity of MCF-7 cells following 
siRNA-mediated E-cadherin suppression. 
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in T47D cells, none of these strategies had any significant 
effect of PELP1 expression (Figure 5E).
Endocrine-induced invasion and migration is 
abrogated in cells lacking PELP-1
In view of this data suggesting a potential link 
between PELP1 and endocrine-induced invasion, we next 
wished to explore whether PELP-1 knockdown in MCF7 
cells would affect their adverse response to endocrine 
agents. PELP1 expression was suppressed by siRNA prior 
to performing invasion and migration assays as previously. 
PELP-1 knockdown greatly reduced the activity of Src, 
AKT and ERK (Figure 6A) along with the endocrine-
induced invasion (Figure 6B and 6C) and migration 
(Figure 6D and 6E) with both tamoxifen and fulvestrant. 
In contrast PELP-1 knockdown had no significant effect 
on cell proliferation (Figure 6F).
Figure 3: Tamoxifen and fulvestrant promote invasion of ER+ breast cancer cells through Src kinase. (A) The effects 
of tamoxifen, fulvestrant or estrogen withdrawal on Src kinase expression and activity (phosphorylation ay Y418) in E-cadherin-positive 
and negative MCF7 models was determined by Western blotting. The ability of the pharmacological Src inhibitor, Saracatinib (1 uM) to 
suppress Src activation was confirmed by Western blotting (B) prior to investigating the ability of Src inhibition to inhibit the pro-invasive 
and pro-migratory effects of tamoxifen (C) and fulvestrant (D) on MCF7 cells ± E-cadherin. Sarcatinib treatment resulted in reduce 
proliferation in MCF7 cells ± E-cadherin (E).
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Figure 4: Tamoxifen and fulvestrant-mediated invasion and migration in ER+ breast cancer cells is ERK, but not 
AKT, dependent. The effects of tamoxifen and fulvestrant treatment on ERK1/2 (A) and AKT (B) activity in MCF7 cells ± E-cadherin 
expression were determined by Western blotting. The ability of the pharmacological inhibitors, U0126 (10 uM) and perifosine (10 uM) to 
suppress ERK1/2 and AKT activity respectively was confirmed by Western blotting (C, G) and the effects of these agents on tamoxifen-
induced cellular invasion further investigated using Boyden chamber assays (U0126: D–F; perifosine: H–J).
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To determine whether PELP1 also contributed to 
the endocrine-induced invasive responses seen to occur 
after E-cadherin loss, we performed a double knockdown 
of PELP1 and CDH1 in MCF7 cells and investigated 
the effects of tamoxifen and fulvestrant on these cells’ 
invasive and migratory nature.  These data revealed that 
the endocrine-induced invasion and migration seen in the 
absence of E-cadherin was suppressed when PELP1 was 
removed (Figure 7A–7C)
DISCUSSION
Adjuvant endocrine therapy has played an important 
role in the management of ER positive breast cancer, 
helping to improve overall and disease-free survival 
considerably over the past few decades [25]. While 
tamoxifen has remained the mainstay of treatment for 
pre-menopausal women over this time-period, more 
recently aromatase inhibitors have played an ever 
more important role in adjuvant therapy. Despite these 
advances, a significant proportion of women still suffer 
disease relapse either while still taking endocrine therapy, 
or after endocrine therapy has been discontinued. In 
addition, unwanted or adverse clinical consequences 
from adjuvant endocrine therapy may be under-reported 
or go unrecognised, leading to relapse and/or disease 
progression. As a result, the optimum choice of endocrine 
agent along with its intended duration remains unclear 
and it may be that as the complex effects of these agents 
become better understood a personalised treatment 
regimen may be more important depending on individual 
tumour biology.
Intriguingly, earlier reports suggest that endocrine 
agents can elicit a pro-invasive response in ER+ breast 
cancer cells that lack E-cadherin mediated cell-cell 
contacts [21]. Moreover, this paper also reported a modest 
increase in invasion in response to endocrine agents 
in E-cadherin competent cells. In our study, we have 
investigated these events further and confirm that an 
endocrine-induced adverse phenotype is apparent in ER+ 
breast cancer cells irrespective of E-cadherin status, albeit 
significantly augmented in the absence of E-cadherin. 
Figure 5: High PELP1 is associated with endocrine-induced invasion and migration in ER+ breast cancer cells. (A) 
PELP1 expression was determined in a panel of ER+ breast cancer cells using Western blotting. Subsequently, the ability of endocrine 
agents to induce invasion and migration in cells displaying low PELP1 expression (T47D) was investigated by Boyden chamber assays (B 
and C). The effects of endocrine agent on PELP1 expression were determined by examining MCF7 and T47D cell lysates using Western 
blotting following endocrine treatment (D and E).
Oncotarget4729www.oncotarget.com
Given these observations, our hypothesis is that both 
tamoxifen and fulvestrant can promote a small gain in 
invasive and migratory behaviour, but these effects do not 
translate into an overly adverse cellular phenotype due to 
the physical constraints imposed by E-cadherin mediated 
cell-cell adhesion. Whilst these events were apparent upon 
exposure to the ER-modulatory agents, tamoxifen and 
fulvestrant, no increase in invasion was seen following 
estrogen withdrawal, as a model of aromatase inhibition.
Our investigation to explore the molecular 
mechanisms underlying these events highlighted a key 
role for Src kinase, with both tamoxifen and fulvestrant 
treatment resulting in an increase in Src activity, whilst 
estrogen withdrawal suppressed Src phosphorylation. 
These findings were independent of E-cadherin status. 
Src kinase has previously been implicated in breast 
cancer metastasis through its role in processes such as 
angiogenesis, focal adhesion and invasion, in conjunction 
with EMT. In terms of angiogenesis, hypoxia has been 
found to activate vascular endothelial growth factor 
(VEGF) through a Src-dependent mechanism [26, 27]. 
Meanwhile breast cancer cell lines have shown an increase 
in Src activity compared with normal breast tissue [8, 
9], while conversely treatment with a pharmacological 
Src inhibitor results in decreased cell motility and a less 
invasive cellular phenotype [11]. Suppression of Src has 
also demonstrated reduced cell migration and attachment 
in MCF-7 cells through a FAK dependent mechanism 
[28], whilst also preventing cell rounding and detachment 
via its interaction with integrin [29]. Consequently, 
pharmacological inhibition of Src phosphorylation using 
Sarcanitib prevented tamoxifen and fulvestrant-induced 
adverse cell behaviour. 
In a similar fashion to that observed when 
investigating Src, our results also demonstrated a role 
for ERK within the mechanism of adverse endocrine 
response. Both tamoxifen and fulvestrant therapy resulted 
in an increase in ERK 1/2 expression, while MEK 
inhibition reversed the previously observed pro-invasive/
pro-migratory response of MCF-7 cells. Stimulation 
of the ER in MCF-7 cells has been shown to result in 
activation ERK in a process involving substrates of Src, 
which subsequently regulate the non-genomic functions 
of the ER in conjunction with Ras [30, 31]. Members of 
the MAPK family, including ERK, have been shown to 
be key regulators of invasion and tumour progression 
in breast cancer, including having roles in secretion of 
matrix metallo-proteinases for ECM degradation [32] 
and guiding cell motility [33]. In contrast to ERK, AKT 
function is more strongly associated with regulation of 
cellular growth, cell cycle progression and cell death 
[34]. AKT expression is also strongly associated with 
the development of tamoxifen resistant in breast cancer 
[35]. AKT is activated by a variety of stimuli through 
growth factor receptors such as HER2 and  EGFR, in a 
PI3K-dependent manner [36]. From our observations 
Figure 6: PELP1 siRNA prevents tamoxifen and fulvestrant-induced pro-invasive responses in ER+ breast cancer cells. 
(A) The effects of PELP1 modulation on internal signalling was determined by treating MCF7 cells with PELP1 siRNA and subsequently 
probing for PELP1, Src, AKT and ERK1/2. The effects of siRNA-mediated PELP1 suppression on endocrine-induced cellular invasion and 
migration were determined through Boyden chamber assays (B–E). PELP1 mediated changes in proliferation were assessed though MTT 
assays (F).
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tamoxifen, fulvestrant and estrogen withdrawal all resulted 
in suppressed activation of AKT in MCF-7 cells and while 
pharmacological inhibition of AKT resulted in suppressed 
cell proliferation, invasion and migration were unaffected. 
Our data further suggests an important link between 
Src and the ER-coactivator, PELP-1, in the phenotypic 
response to endocrine agents. In addition to an increase 
in Src activation with both tamoxifen and fulvestrant, 
our data also demonstrate that both drugs appear to 
increase total expression of PELP-1 as compared to 
controls. As such, it may be possible that either PELP-1 
is directly activated through an unanticipated effect of ER 
modulation and antagonism and/or that total levels PELP-
1 levels are upregulated via a nuclear function of the ER 
cascade. It is also interesting to note that basal expression 
of PELP-1 was higher in MCF-7 cells when compared to 
T47D, a finding that has also previously been reported by 
others [17]. Tamoxifen and fulvestrant also appeared to 
have no effect on total levels of PELP-1 in T47D cells, in 
contrast to the MCF-7 cell line. It may therefore follow 
that the adverse response seen in MCF-7 cells may be 
absent from the T47D cell line because of this lower and 
unregulated expression of PELP-1 expression.
Importantly, whilst our data supports the role of 
a possible interaction between PELP-1 and Src kinase, 
brought about by the action of endocrine agents on the 
ER, further investigations are required to determine the 
exact nature of this interaction. Whilst PELP-1 has been 
shown to interact with the SH3 domain of Src via its first 
N terminal PxxP domain [37], its relationship based on 
the ligand binding status of the ER appears less clear. 
Given the increased expression of Src observed with both 
tamoxifen and fulvestrant, one would assume this change 
to be related to the antagonistic functions of the ER, 
possible resulting in ER-independent PELP1-mediated 
Src activation.
Although PELP-1 knockdown resulted in reduced 
invasion and migration in MCF-7 cells, proliferation 
appeared to be unaffected. This finding is despite 
PELP-1 knockdown resulting in lower Src kinase 
expression, which we have previously shown to have a 
significant negative effect of proliferation, in terms of 
pharmacological inhibition at least. This may mean that 
PELP-1 may be a more specific target for invasion and 
migration as opposed to a Src kinase itself, although 
it is interesting to note that as PELP-1 is a substrate of 
cyclin dependent kinase’s (CDK’s) [38], which regulates 
proliferation, while mechanistic studies have found that 
PELP-1 may play a permissive role in E2-mediated cell 
cycle progression [20, 39]. Whilst it would appear PELP-
1 may be a potential future target for drug therapies, 
no direct inhibitors are currently available. Instead an 
alternative approach could be to target the downstream 
interactions of PELP-1, including Src, MEK/ERK and 
CDK2 [39], although the effects of these treatments may 
not have the same specificity as targeting PELP-1 itself. 
As a result, future drug development aiming to inhibit 
PELP-1 function itself, may be a potential avenue of 
future exploration. 
Here we have demonstrated that while tamoxifen 
and fulvestrant resulted in an increase in invasion and 
migration on MCF-7 cells, estrogen suppression resulted 
in the opposite effect. These data again suggest that 
aromatase inhibition may therefore be a more appropriate 
treatment in tumours with low intrinsic expression of 
E-cadherin. While our data supports this hypothesis, it 
is also interesting to note that aromatase inhibition led 
to suppressed total levels of PELP-1 expression and 
reduced expression of Src kinase signalling, which further 
implicates PELP-1 as a potentially crucial regulator if this 
process. The importance of these observations have been 
recently investigated clinically, which further reveal that 
patients with ER positive cancers with low expression of 
E-cadherin have poorer disease free survival when treated 
with tamoxifen as compared to aromatase inhibitors [40]. 
Treatment of breast cancer is becoming more 
personalised with better understanding of tumour biology. 
Recent developments have generated tools, such as 
Figure 7: PELP 1 suppressed endocrine-induced invasion and migration in the absence of E-cadherin. Cells were treated 
with siRNA against PELP1 ± CDH1 (A) and treated with endocrine agents and the invasive and migratory capacity of these cells assessed 
through Boyden chamber assay (B and C). 
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Oncotype DX®, which predicts the benefit of adjuvant 
chemotherapy based on the expression of 21 cancer-related 
genes [41]. Predictors of response to adjuvant endocrine 
therapy, outside of ER and PR expression, is currently less 
developed however. Identification of biological markers 
that could predict response to treatment may therefore 
prove valuable when deciding on an optimum choice of 
endocrine therapy. The results demonstrated in this paper 
would suggest that ongoing work to assess how E-cadherin 
and/or PELP-1 may be of value in this context would be 
of value. 
MATERIALS AND METHODS
Cell culture
ER+, endocrine sensitive MCF-7 and T47D cells 
were routinely cultured in glutamine-supplemented 
RPMI medium (Invitrogen, Paisley, UK), supplemented 
with 5% foetal calf serum (FCS), antibiotics (10I U/ml 
penicillin and 10 μg/ml streptomycin) and fungi-zone (2.5 
μg/ml), and incubated at 37°C with 5% carbon dioxide. 
For experimental analysis, the medium was changed to 
experimental medium, containing phenol-red-free RPMI 
supplemented with 5% FCS, 100 mM glutamine and 
antibiotics as above. For estrogen withdrawal conditions 
(-E2) the FCS within the experimental medium was 
replaced with 5% charcoal-stripped, steroid-depleted 
FCS, while for anti-estrogen and hormone treatments the 
medium was supplemented with 10-9 M estradiol (E2), 
10-7 M 4-hydroxytamoxifen (‘Tam’) or 10-7 M fulvestrant 
(‘Fas’). All tissue culture media and constituents were 
obtained from Life Technology Europe Ltd (Paisley, UK) 
and tissue culture plasticware was obtained from Nunc 
(Rosklide, Denmark).
Antibodies and reagents
The antibodies used were: anti-phospho Src kinase 
(Y418) and pan-Src kinase (Invitrogen, Paisley, UK), anti-
phospho AKT (ser473), pan-AKT, anti-ERK 1/2, pan-ERK 
1/2 and pan-PELP-1 (Cell Signalling Technologies, Herts, 
UK), anti E-cadherin antibody (R&D Systems Ltd, Oxford 
UK), anti-glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (ABCAM, Cambridge, UK) and anti-β-Actin 
(Sigma-Aldrich, Poole, Dorset, UK).
siRNA-mediated suppression of PELP-1 and 
E-cadherin
SMARTpool siRNA against human PELP-1 gene 
and human E-cadherin gene (CDH1) respectively were 
obtained from Dharmacon Ltd (Perbio Science UK 
Ltd, Northumberland, UK) and used according to the 
manufacturer instructions. Cells were seeded into 35 mm 
dishes at 104 cells/dish in antibiotic-free experimental 
medium with or without anti-hormone as appropriate. 
After 24 hours of cell culture, the medium was replaced 
with fresh, antibiotic-free medium containing transfection 
lipid, 100 nM of non-targeting siRNA control (NT), 100 
nM SMARTpool siRNA specific for PELP-1 or CDH1, 
or 50 nm SMARTpool siRNA specific for PELP-1 plus 
50 nm SMARTpool siRNA specific for CDH1 where 
knockdown of both targets was required. Cells were 
assayed for PELP-1/E-cadherin protein expression after 
24, 48 and 72-hours post-transfection by Western blotting 
to confirm protein knockdown. For invasion assays and 
Western blotting analysis, cells were treated with PELP-
1/CDH1 siRNA for 72 hours before performing the 
experiments in the presence or absence of the agents as 
detailed. 
Basement membrane invasion assay
Cell invasion was determined using invasion 
chambers possessing an 8 μm porous membrane (BD 
Biosciences, Oxford, UK) coated with a 50 μl of 1:3 ratio 
or Matrigel:wRPMI. Cells (treated as above) were seeded 
into the top of each chamber (5 × 104 cells/well) with or 
without anti-hormone treatment, while 650 μl of medium 
was added to the lower chamber of the well. Inserts 
were cultured at 37°C in a tissue culture incubator for 48 
hours, after which the non-invasive cells and Matrigel 
were removed from the upper chamber of the insert 
with a cotton swab. The invasive cells on the underside 
of the insert was fixed with 3.7% formaldehyde, before 
the porous membrane of the insert was, detached using a 
scalpel blade and mounted onto a glass microscope slide 
using Vectashield (Molecular Probes, Eugene, OR, USA) 
containing the nuclear stain 4′,6-diamidino-2-phenylindole 
(DAPI). Cell invasion was quantified by viewing ten 
separate fields per membrane at a magnification of ×10 
and counting the number of cells in each field. Data was 
then plotted as the total number of cells counted per insert 
+/– SD for a minimum of three independent biological 
replicates of the experiment.
Cell migration assay
Cell migration was determined using invasion 
chambers possessing an 8 μm porous membrane (BD 
Biosciences, Oxford, UK) coated with an air-dried 
solution of fibronectin mixed with RPMI (1:100). Cells 
(treated as above) were seeded into the top of each 
chamber (4 × 104 cells/well) with or without anti-hormone 
treatment, while 650 μl of medium was added to the lower 
chamber of the well. Inserts were cultured at 37°C in a 
tissue culture incubator for 24 hours, after which the non-
invasive cells and Matrigel were removed from the upper 
chamber of the insert with a cotton swab. The migratory 
cells on the underside of the insert were fixed with 3.7% 
formaldehyde, before the insert was stained with crystal 
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violet solution. Cell migration was quantified by viewing 
ten separate fields per membrane at a magnification of ×10 
and counting the number of cells in each field. Data was 
then plotted as the total number of cells counted per insert 
+/– SD for a minimum of three independent biological 
replicates of the experiment.
Cell lysis and western blotting
After cell culture were treated as described above, 
cells were washed twice with ice-cold PBS and lysed in 
lysis buffer (50 mM Tris, pH 7.5, 5 mM EGTA, 150 mM 
NaCl, 1% Trixton X100) containing protease inhibitors (2 
mM sodium orthovanadate, 20 mM sodium fluoride, 1 mM 
phenyl-methylsulfonyl fluoride, 20 μM phenylarsinine, 
10 μM sodium molybdate, 10 μg/ml leupeptin and 8 μg/
ml aprotinin). The lysates were then placed on ice for 
20 minutes and clarified by centrifugation (15 minutes, 
15,000 rpm, 4°C). The concentration of solubilised 
proteins was then determined using the DC protein assay 
kit (BioRad, Hemel Hempstead, UK). Using these lysates, 
20 μg of total protein was separated by SDS-PAGE using 
10% gels and transferred to nitrocellulose membranes 
by electroblotting. Membranes were then blocked using 
5% (w/v) milk protein in Tris-buffered saline containing 
0.05% Tween-20 and incubated with primary, followed by 
secondary horseradish peroxidase-conjugated secondary 
antibodies. An enhanced chemiluminescence system 
(West ECL reagent, Pierce and Warriner Ltd, Chester, UK) 
was used for detection of bound antibodies by exposing 
the blots to X-ray film (Kodak, UK). Blots shown are 
representative of a minimum of three separate biological 
replicates of the experiment.
Cell proliferation assay(s)
For the MTT assay, cells were seeded into a 96-well 
plate (1 × 106cells/plate) and, after 24 hours, appropriate 
treatment were added, as described, and cells cultured for 
a further 72 hours. For analysis of the effects of PLEP-1/
CDH1 knockdown on basal growth rates, cells were pre-
treated with siRNA, seeded into the plates and cultured 
for 72 hours with no further treatment. Cells were then 
washed gently with warm phosphate buffered saline 
(PBS) and incubated with 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazolium dehydrogenase (MTT) 
at 37°C for 4 hours to allow formation of formazan 
crystals within mitochondria. The MTT was then 
replaced with Trixton-X-100 (Sigma-Aldrich, Poole, 
Dorset, UK) and the plate maintained at 4°C overnight, 
to allow the formazan crystals produced to be released 
from mitochondria and dissolve. Data was obtained by 
recording the optical density of each well using an ELISA 
plate reader (mean of eight separate wells per condition), 
with experiments repeated using a minimum of three 
biological replicates.
Statistical analysis
All graphical data is presented using the Prism 
Graphpad® version 6 statistical software. Statistical 
analysis was performed using SPSS® 20. Statistical 
significance was determined by a p-value of < 0.05. For 
analysis of data comparing two independent variables an 
independent samples t-test was performed where data 
followed a normal distribution, while a Mann-Whitney 
test was performed in cases where the data was deemed to 
be non-parametric. For comparison of multiple variables, 
a one-way ANOVA test was performed to assess for a 
significance across the dataset, with a post-hoc Bonfferoni 
test used to assess significance between two of the 
variables within the dataset. 
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